塞力医疗拟向武汉华纪元增资4274.29万元

Core Viewpoint - The company, Saily Medical (603716.SH), plans to increase its stake in Wuhan Huajiyuan by investing 42.74 million yuan, raising its ownership to 41% [1] Group 1: Investment Details - The actual controller, Mr. Wen Wei, intends to acquire 10% equity from shareholder Sun Danping for 27.2 million yuan, based on a post-investment valuation of 272 million yuan [1] - The total investment from the company and Mr. Wen Wei amounts to 69.94 million yuan [1] - Other shareholders of Wuhan Huajiyuan have waived their preemptive rights regarding the equity transfer [1] Group 2: Strategic Implications - The investment will provide additional funding to Wuhan Huajiyuan, supporting the development of its therapeutic hypertension vaccine project (HJY-ATRQβ-001) through various clinical trial phases [1] - This move aligns with the company's strategic transformation plan, optimizing its business structure and enhancing core competitiveness [1] - The target company is expected to be included in the company's consolidated financial statements as a controlled subsidiary by 2026 [1]